NCT02616211

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 15 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.

Detailed description

In order to improve the treatment outcome for thoracic carcinomas after they become resistant to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for genomic analysis to identify novel somatic changes in critical genes and gene pathways that can potentially be targeted with therapy. The study team is also creating patient-derived xenografts to test drug efficacy and optimize personalized therapy for each patient.

Conditions

• Adenocarcinoma of Lung
• Lung Neoplasm
• Cancer of Lung
• Lung Cancer
• Pulmonary Cancer
• EGFR Genes
• ALK Genes

Timeline

• Start date: 2014-10-01
• Primary completion: 2018-10-01
• Completion: 2019-12-01
• First posted: 2015-11-26
• Last updated: 2020-10-19

Locations

1 site across 1 country: United States